Weiss Ratings reiterated their sell (d-) rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research note released on Saturday,Weiss Ratings reports. A number of other research analysts also ...

Inc.'s results from ENTRUST study on pegozafermin for Severe Hypertriglyceridemia expected in 2025. Click for this updated ...

Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in ...

Inc. (NASDAQ:ETNB – Get Free Report)’s share price hit a new 52-week low during trading on Friday following insider selling activity. The stock traded as low as $5.99 and last traded at $6.09, with a ...

H.C. Wainwright reiterated its Buy rating and $29.00 price target for 89bio Inc . (NASDAQ:ETNB) shares. According to InvestingPro data, the stock currently trades at $6.31, near its 52-week low of $5.

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on January 2.Stay Ahead of the ...

(ETNB) provided a corporate update and business outlook for 2025. Completed enrollment in Phase 3 ENTRUST trial in patients with severe ...

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The ...

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options.

CEO of 89bio. “We remain confident in pegozafermin’s potential as a potent anti-fibrotic agent with broad cardio-metabolic benefits. With a strengthened leadership team, commercial-scale ...